La Trobe

T cell factor 1 (TCF-1) Defines T cell Differentiation in Colorectal Cancer

Download (4.45 MB)
journal contribution
posted on 2024-09-18, 03:29 authored by Kelly TranKelly Tran, Anita Narendra KUMARI, Dinesh Raghu, Daniel RA Cox, Su Kah Goh, Marcos V Perini, Vijayaragavan Muralidharan, Niall TebbuttNiall Tebbutt, Andreas BehrenAndreas Behren, John MariadasonJohn Mariadason, David WilliamsDavid Williams, Lisa MielkeLisa Mielke

SUMMARY: The presence of precursor to exhausted (Tpex) CD8+ T cells is important to maintain robust immunity following treatment with immune checkpoint inhibition (ICI). Impressive responses to ICI are emerging in patients with stage II-III mismatch repair (MMR)-deficient (dMMR) colorectal cancer (CRC). We found 64% of dMMR and 15% of mismatch repair-proficient (pMMR) stage III CRCs had a high frequency of tumor infiltrating lymphocytes (TIL-hi). Furthermore, expression of TCF-1 (Tcf7) by CD8+ T cells predicted improved patient prognosis and Tpex cells (CD3+CD8+ TCF-1+PD-1+) were abundant within lymphoid aggregates of stage III CRCs. In contrast, CD3+CD8+TCF-1?PD-1+ cells were more abundant at the invasive front and tumor core, while gd T cells were equally abundant in all tumor areas. Interestingly, no differences in the frequency of Tpex cells were observed between TIL-hi dMMR and TIL-hi pMMR CRCs. Therefore, Tpex cell function and ICI response rates in TIL-hi CRC warrants further investigation. 

Funding

This research was funded by The Australian National Health and Medical Research Council Ideas Grants 2011558 (L.A.M.) and 1185513 (L.A.M. and D.W.), Victorian Cancer Agency mid-career and early career fellowships (L.A.M. and D.R.), Cure Cancer Australia, Priority Driven Young Investigator Grant 1123388 (L.A.M.) and Veski Career Recovery Grant (L.A.M.)

History

Publication Date

2024-09-20

Journal

iScience

Volume

27

Issue

9

Article Number

110754

Pagination

13p.

Publisher

Elsevier

ISSN

2589-0042

Rights Statement

© 2024 The Author(s). Published by Elsevier Inc.This is an open access article under the CC BY-NC-ND license: http://creativecommons.org/licenses/by-nc-nd/4.0/